Currently,ischemic stroke remains one of the most costly and devastating clinical syndromes,accounting for 9%of all deaths and being the second leading cause of death in the world(Davidson et al.,2018).Approximately 20%of strokes are caused by intracerebral hemorrhage,while the other^80%are classified as ischemic.With the discovery of thrombolysis,reperfusion therapy became an option for the treatment of ischemic stroke.More recently,endovascular recanalization with mechanical thrombectomy has brought about a paradigm shift in the optimal management of patients with large vessel occlusion.Importantly,early reperfusion is the only therapy that is proven to limit infarct size in patients with acute ischemic stroke.However,despite a successful recanalization being achieved in more than 70% of patients treated with mechanical thrombectomy+/–intravenous tissue recombinant plasminogen activator,functional independence(modified Rankin score 0–2 at 3 months after ischemic stroke)is obtained only in^45% of cases.This reveals the further need to develop new adjunctive neuroprotective treatment strategies alongside reperfusion therapy.
展开▼
